RECRUITING

Bladder Directed Vs. Pelvic Floor Therapy in IC/BPS

Conditions

Cystitis, Interstitial Painful Bladder Syndrome

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Women with interstitial cystitis/bladder pain syndrome (IC/BPS) have debilitating urinary frequency and urgency, and chronic pelvic or bladder pain perceived to be related to the bladder. Although many clinicians think that IC/BPS symptoms result from a bladder problem, tight pelvic floor muscles can cause similar symptoms and might be responsible for ICBPS symptoms instead of the bladder. Inadequate assessment of the problem leads to delays in treatment and often years of suffering. This clinical trial will test a bladder directed therapy (bladder instillations) compared to a course of pelvic floor physical therapy (PFPT) to assess the role of the pelvic floor as a major contributor to pelvic pain and voiding dysfunction in adult women with non-ulcerative IC/BPS. Early assessment of the pelvic floor muscles in patients with IC/BPS symptoms may prevent common delays in proper diagnosis and allow for early, more effective treatment.

Official Title

Comparison of Bladder Directed and Pelvic Floor Therapy in Women with Interstitial Cystitis/Bladder Pain Syndrome

Quick Facts

Study Start:2017-04-21

Study Completion:2025-08

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT02870738

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 85 Years

Sexes Eligible for Study:FEMALE

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Female * Age 18 to 85 years * History of patient self-reported of IC/BPS symptoms for at least 6 months. * Using an approved method of birth control, or surgically sterile, or of non-child bearing age with no menstrual period for the past 12 months * Must be willing to not start any new medication known to affect bladder or muscle function, and to ideally remain on a stable dose of all other medications through the secondary endpoint.	* Active urethral or ureteral calculi, urethral diverticulum, history of pelvic radiation therapy, tuberculous cystitis, bladder cancer, carcinoma in situ (bladder), urethral cancer * Hunner's lesions found on screening cystoscopy * Prior investigational or therapeutic bladder instillations for IC/BPS symptoms within the past 3 months * Lactation, pregnancy, or refusal of medically approved/reliable birth control in women of child-bearing potential. * Pain, frequency, and/or urgency symptoms only present during menses * Clinically confirmed urinary tract infection at time of screening * Participant unable to tolerate insertion of one or two vaginal examining fingers (e.g. Vulvar allodynia) * Participant had prior course of physical therapy (PT) that included internal (vaginal and/or rectal) manual therapy with connective tissue manipulation by physical therapist for the same symptoms within the past 3 months (prior treatment by therapist with biofeedback, electrical stimulation, or pelvic floor exercises is not exclusionary) * Participant in the opinion of the investigator has a relevant neurologic disorder that affects bladder and/or neuromuscular function * Participant has/reports any severe, debilitating or urgent concurrent, medical condition * Participant has a potentially significant pelvic pathology or abnormality on examination or prior imaging, including prolapse beyond the hymenal ring, pelvic mass, etc., that in the investigators' judgment, could cause or contribute to the clinical symptoms, or require treatment * Any other condition which, in the investigator's judgment, may increase risk to subject's welfare * Participation in an investigational trial that uses a study treatment less than 6 months from the date of the screening visit

Inclusion Criteria

Exclusion Criteria

* Female
* Age 18 to 85 years
* History of patient self-reported of IC/BPS symptoms for at least 6 months.
* Using an approved method of birth control, or surgically sterile, or of non-child bearing age with no menstrual period for the past 12 months
* Must be willing to not start any new medication known to affect bladder or muscle function, and to ideally remain on a stable dose of all other medications through the secondary endpoint.

* Active urethral or ureteral calculi, urethral diverticulum, history of pelvic radiation therapy, tuberculous cystitis, bladder cancer, carcinoma in situ (bladder), urethral cancer
* Hunner's lesions found on screening cystoscopy
* Prior investigational or therapeutic bladder instillations for IC/BPS symptoms within the past 3 months
* Lactation, pregnancy, or refusal of medically approved/reliable birth control in women of child-bearing potential.
* Pain, frequency, and/or urgency symptoms only present during menses
* Clinically confirmed urinary tract infection at time of screening
* Participant unable to tolerate insertion of one or two vaginal examining fingers (e.g. Vulvar allodynia)
* Participant had prior course of physical therapy (PT) that included internal (vaginal and/or rectal) manual therapy with connective tissue manipulation by physical therapist for the same symptoms within the past 3 months (prior treatment by therapist with biofeedback, electrical stimulation, or pelvic floor exercises is not exclusionary)
* Participant in the opinion of the investigator has a relevant neurologic disorder that affects bladder and/or neuromuscular function
* Participant has/reports any severe, debilitating or urgent concurrent, medical condition
* Participant has a potentially significant pelvic pathology or abnormality on examination or prior imaging, including prolapse beyond the hymenal ring, pelvic mass, etc., that in the investigators' judgment, could cause or contribute to the clinical symptoms, or require treatment
* Any other condition which, in the investigator's judgment, may increase risk to subject's welfare
* Participation in an investigational trial that uses a study treatment less than 6 months from the date of the screening visit

Contacts and Locations

Study Contact

Lydia Kosovich, RN

CONTACT

248-551-3291

Lydia.Kosovich@Beaumont.org

Principal Investigator

Kenneth M Peters, MD

PRINCIPAL_INVESTIGATOR

Beaumont Hospital-Royal Oak

Study Locations (Sites)

William Beaumont Hospital

Royal Oak, Michigan, 48073

United States

Collaborators and Investigators

Sponsor: William Beaumont Hospitals

Kenneth M Peters, MD, PRINCIPAL_INVESTIGATOR, Beaumont Hospital-Royal Oak

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-04-21

Study Completion Date2025-08

Study Record Updates

Study Start Date2017-04-21

Study Completion Date2025-08

Terms related to this study

Additional Relevant MeSH Terms

Cystitis, Interstitial
Painful Bladder Syndrome